Absci Corp

Absci Corporation is a clinical-stage biopharmaceutical company that designs and develops differentiated antibody therapeutics using an artificial intelligence platform integrated with laboratory testing. Its operations include an internal pipeline of drug candidates as well as partnered discovery programs. The company’s lead investigational therapeutic, ABS-201, targets prolactin receptor signaling to treat androgenetic alopecia and endometriosis. Absci also develops additional antibody programs, such as ABS-101, alongside early-stage oncology and immunology candidates. The firm collaborates with external pharmaceutical and biotechnology companies, offering AI-guided antibody discovery, de novo protein design, and lead optimization services to support partners' development pipelines.

The company conducts operations utilizing a combined wet-laboratory and dry-laboratory facility that spans more than 77,000 square feet. Its clinical development activities include multi-site clinical trials in Australia for its lead therapeutic candidate, while its business partnerships involve multinational pharmaceutical enterprises. The provided text does not state the location of the company's corporate headquarters.

Summary of the business section of Absci's latest annual report, written by StockData.

“As of December 31, 2025, we had 140 employees, many of whom have advanced post-graduate degrees, primarily engaged in research and development and general and administrative functions.”